公开(公告)号：US11524957B2

公开(公告)日：2022-12-13

申请号：US17044366

申请日：2019-04-01

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Lei Zhu ,  John Daniel Bailey ,  Landon Durak ,  Joshua David Waetzig ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Hiroshi Yamaguchi ,  Koichiro Fukuoka ,  Kazuyuki Akiyama

IPC分类号： C07D453/02 ,  C07D409/04

摘要： The present invention provides processes and synthetic intermediates for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 {3H)-one or a salt, hydrate, or tautomer thereof, or any combination thereof, which are Cdc7 kinase inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with Cdc7 activity.

公开(公告)号：US20210101897A1

公开(公告)日：2021-04-08

申请号：US17044366

申请日：2019-04-01

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Lei Zhu ,  John Daniel Bailey ,  Landon Durak ,  Joshua David Waetzig ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Hiroshi Yamaguchi ,  Koichiro Fukuoka ,  Kazuyuki Akiyama

IPC分类号： C07D453/02 ,  C07D409/04

摘要： The present invention provides processes and synthetic intermediates for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one or a salt, hydrate, or tautomer thereof, or any combination thereof, which are Cdc7 kinase inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with Cdc7 activity.